These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29500218)

  • 1. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model.
    French RA; Samelson-Jones BJ; Niemeyer GP; Lothrop CD; Merricks EP; Nichols TC; Arruda VR
    Blood Adv; 2018 Mar; 2(5):505-508. PubMed ID: 29500218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
    Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
    Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
    Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
    Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
    Larson PJ; High KA
    Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy, an ongoing revolution.
    Benveniste O
    Blood; 2012 Mar; 119(13):2973-4. PubMed ID: 22461470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
    Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
    Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
    Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
    Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.
    Arruda VR; Stedman HH; Nichols TC; Haskins ME; Nicholson M; Herzog RW; Couto LB; High KA
    Blood; 2005 May; 105(9):3458-64. PubMed ID: 15479726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
    Jiang H; Pierce GF; Ozelo MC; de Paula EV; Vargas JA; Smith P; Sommer J; Luk A; Manno CS; High KA; Arruda VR
    Mol Ther; 2006 Sep; 14(3):452-5. PubMed ID: 16822719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
    Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
    Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexity of immune responses to AAV transgene products - Example of factor IX.
    Herzog RW
    Cell Immunol; 2019 Aug; 342():103658. PubMed ID: 28645365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.